Comparative Pharmacology
Head-to-head clinical analysis: HYDRO D versus HYGROTON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRO D versus HYGROTON.
HYDRO-D vs HYGROTON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, reducing sodium and water reabsorption and increasing potassium excretion.
Inhibits sodium reabsorption in the distal convoluted tubule by binding to the thiazide-sensitive sodium-chloride cotransporter (NCC), leading to increased excretion of sodium, chloride, and water.
25-100 mg orally once daily in the morning.
25-50 mg orally once daily; may increase to 100 mg once daily for resistant hypertension or edema. Maximum dose 100 mg/day.
None Documented
None Documented
Terminal elimination half-life: 5.6 to 15 hours; prolonged in renal impairment and in patients with heart failure.
Terminal elimination half-life is approximately 40-50 hours, extending up to 70 hours in patients with renal impairment, allowing for once-daily dosing.
Renal: approximately 50% as unchanged drug; biliary/fecal: approximately 50% as metabolites and minor unchanged drug.
Renal (approximately 50-60% as unchanged drug and metabolites); biliary/fecal elimination accounts for a minor fraction, less than 10%.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic